^
Association details:
| Biomarker: | KDM6A underexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | 5-fluorouracil (Thymidylate synthase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
[KDM6A mutation and expression in gastric cancer are associated with prognosis]
Published date:
08/23/2020
Excerpt:
In male, gastric cancer patients with stage Ⅲ, intestinal type, diffuse type, simple surgical treatment and fluorouracil chemotherapy, the expression of KDM6A is related to the patient's overall survival time (all P<0.05)….The survival time of gastric cancer patients with KDM6A mutation or low expression is shorter.
DOI:
10.3760/cma.j.cn112152-20190528-00334
